Online Inquiry

Global Services. (Creative Biolabs Authorized)

Host Cell Residual Impurity Quantification (HCD & HCP) Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The reliable production of cell and gene therapies is often hindered by critical challenges, including the need to monitor acute host tissue toxicities during in vivo genetic modification and to enforce rigorous quality control over the integrity of targeting ligands and encapsulation consistency of viral coats or LNP formulations. To address these hurdles, we offer our specialized Host Cell Residual Impurity Quantification (HCD & HCP) Service. Our service provides precise, high-sensitivity analytical solutions tailored specifically for the detection and quantification of host cell DNA and proteins. By leveraging advanced methodologies and stringent quality standards, our service ensures robust safety profiling and process consistency, ultimately delivering the critical data you need to accelerate program timelines and satisfy regulatory requirements with confidence.

Introduction

Residual host-cell DNA (HCD) is a critical safety contaminant in In vivo CAR therapy products, carrying potential oncogenic and infectious risks that demand rigorous clearance monitoring. Host-cell proteins (HCPs), as the major process-related impurities, pose significant immunogenicity concerns and can compromise product stability and biological activity if not adequately controlled. Quantitative analysis of both HCD and HCP residuals therefore serves as an indispensable quality attribute assessment, providing essential safety and purity data that guide process development, establish clearance validation, and support regulatory filings for submissions.

Fig.1 Three pre-analytical treatment protocols for HCP detection workflows. (OA Literature) Fig.1 Three pretreatment strategies for the analysis of host-cell proteins.¹

Our Service

Our Host Cell Residual Impurity Quantification Service for In vivo CAR therapy delivers precise, regulatory-ready detection of residual HCD and HCPs across all stages of vector and cell product development. Leveraging validated platforms, we provide high-sensitivity, matrix-compatible analysis that ensures product safety, minimizes immunogenicity risks, and accelerates your studies with reliable, actionable data.

What We Can Offer

Our service delivers a fully integrated suite of orthogonal analytical solutions for host cell impurity quantification, combining regulatory-ready HCD detection with complementary HCP screening and deep-profiling capabilities to ensure product safety, purity, and process consistency for your in vivo CAR therapy programs.

Featured services of host cell residual impurity quantification (HCD & HCP) service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Cell products at pilot scale or end-of-production, purification intermediates, or final drug products.
Biological matrix samples collected after in vivo administration.
HCP/HCD reference standards.

Key Steps:

Workflow of host cell residual impurity quantification (HCD & HCP) service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Test Results and Concentration Values.
Method Validation Data.
Raw Data and Analytical Plots/Chromatograms.

Key Advantages

Ensured Product Safety and Therapeutic Efficacy: We directly mitigate critical safety liabilities and preserve therapeutic potency by precisely quantifying residual host-cell DNA and proteins, which are well-established risk factors for immunogenicity and adverse clinical outcomes.
Streamlined Operational Efficiency: We integrate automated solutions across the entire workflow from sample preparation to final quantification, which consistently improve sample recovery rates while significantly reducing hands-on time and turnaround.
Comprehensive Platform Versatility: We offer a flexible analytical portfolio that accommodates diverse host cell lines and sample matrices, providing tailored solutions for both early-stage process development and late-stage lot release testing.

FAQ

Q1: What host cell impurities are typically targeted in these assays?

A1: Our service primarily quantifies two categories of residual impurities derived from the production cell line. The first is HCD, measured via quantitative PCR (qPCR) to monitor both residual amount and fragment size distribution. The second is HCP, assessed using ELISA with broadly representative, high-sensitivity antibody kits to ensure comprehensive coverage of potential immunogenic species.

Q2: What methodological requirements must be considered for in vivo CAR products?

A2: Given the direct systemic administration of these therapies, analytical methods demand rigorous performance criteria. Full validation is mandatory, with limits of detection and quantification sufficiently low to trace trace-level impurities. Matrix effects such as interference from lipid nanoparticles (LNPs) or viral vectors must be thoroughly evaluated for both qPCR and ELISA platforms. Beyond HCD/HCP, other process-related contaminants also require monitoring to meet comprehensive safety standards.

Why Choose Us?

We combine deep expertise in in vivo CAR therapy with rigorous analytical science to deliver accurate, reliable, and regulatory-ready HCD/HCP quantification. Our platform ensures ultra-high sensitivity and streamlined automated workflows, providing you with robust impurity data that safeguard product safety and accelerate your path to the clinic.

Customer Reviews

"During the regulatory submission process for our in vivo CAR-T program, the HCD and HCP quantitative data provided by Creative Biolabs' service proved instrumental in paving our path forward. Their team not only executed a comprehensive method validation in full alignment with current regulatory guidelines but also delivered a meticulously structured validation report that demonstrated exceptional rigor. The report comprehensively covered critical parameters including specificity, accuracy, and achieved exceptionally low limits of quantification (LOQ), providing us with the robust data package necessary to confidently address regulatory expectations." CMC Lead.

"Our HEK293T transient transfection platform presents significant analytical complexity, and off-the-shelf HCP kits had previously caused substantial false-positive interferences that hampered our process understanding. The adoption of Creative Biolabs' tailored quantification service marked a turning point. Their scientific team conducted an in-depth HCP antibody coverage study specifically targeting our proprietary production cell line and critical process intermediates. Based on these insights, they provided a highly specific, customized kit that effectively eliminated non-specific cross-reactivity, enabling us to accurately profile impurity clearance for the first time." Analytical Scientist.

How to contact us?

Our scientific team is ready to discuss your specific program needs from method suitability to regulatory strategy. Whether you are at an early discovery stage or preparing IND-enabling studies, we offer tailored solutions with rapid response. Reach out to initiate a confidential technical consultation and receive a customized proposal aligned with your project timeline.

Reference

Yao, Yifan et al. "Residual host cell proteins: sources, properties, detection methods and data acquisition modes." Frontiers in microbiology vol. 16 1658366. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2025.1658366.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.